Literature DB >> 16001767

Retinal vascular disease in hypertension. Risk factor modification optimizes vision outcomes.

Michael Colucciello1.   

Abstract

In a previous article (July 2004, page 57), Dr Colucciello reviewed nonproliferative and proliferative diabetic retinopathy. In this article, he discusses retinal vascular disease associated with hypertension, which is especially likely to occur in persons with vasculopathic risk factors. Retinal vein occlusion, retinal arterial macroaneurysm, retinal artery occlusion, and carotid artery disease are predictive of progressive systemic vascular disease. Modification of risk factors and prompt identification of retinal vascular disease optimize vision outcomes and preserve quality of life.

Entities:  

Mesh:

Year:  2005        PMID: 16001767     DOI: 10.3810/pgm.2005.06.1662

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  3 in total

1.  Retinal ischemia induces α-SMA-mediated capillary pericyte contraction coincident with perivascular glycogen depletion.

Authors:  Luis Alarcon-Martinez; Sinem Yilmaz-Ozcan; Muge Yemisci; Jesse Schallek; Kıvılcım Kılıç; Deborah Villafranca-Baughman; Alp Can; Adriana Di Polo; Turgay Dalkara
Journal:  Acta Neuropathol Commun       Date:  2019-08-20       Impact factor: 7.801

2.  Ly6c as a New Marker of Mouse Blood Vessels: Qualitative and Quantitative Analyses on Intact and Ischemic Retinas.

Authors:  Marina Martínez-Carmona; Fernando Lucas-Ruiz; Alejandro Gallego-Ortega; Caridad Galindo-Romero; María Norte-Muñoz; María José González-Riquelme; Francisco J Valiente-Soriano; Manuel Vidal-Sanz; Marta Agudo-Barriuso
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

3.  Corkscrew retinal vessels and retinal arterial macroaneurysm in a patient with neurofibromatosis type 1: A case report.

Authors:  Jia Lu; Haiyan Liu; Lin Zhang; Lingjun Ma; Hongyan Zhou
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.